<SEC-DOCUMENT>0001004878-13-000225.txt : 20130719
<SEC-HEADER>0001004878-13-000225.hdr.sgml : 20130719
<ACCEPTANCE-DATETIME>20130719162639
ACCESSION NUMBER:		0001004878-13-000225
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130718
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20130719
DATE AS OF CHANGE:		20130719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		13977285

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8kitem301july-13.txt
<DESCRIPTION>FORM 8-K ITEM 3.01
<TEXT>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): July 18, 2013


                               CEL-SCI CORPORATION
                    ---------------------------------------
             (Exact name of Registrant as specified in its charter)



      Colorado                        01-11889                  84-0916344
--------------------          ------------------------    ----------------------
(State or other jurisdiction    (Commission File No.)     (IRS Employer
of incorporation)                                           Identification No.)


                         8229 Boone Boulevard, Suite 802
                             Vienna, Virginia 22182
              ----------------------------------------------------
          (Address of principal executive offices, including Zip Code)



       Registrant's telephone number, including area code: (703) 506-9460



                                       N/A
                ------------------------------------------------
          (Former name or former address if changed since last report)

<PAGE>

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.

     CEL-SCI  Corporation  ("CEL-SCI")  received a communication  dated July 18,
2013  from the  staff of the NYSE MKT LLC (the  "Exchange")  that,  based on the
Exchange staff's review of publicly available information, CEL-SCI was deemed to
be noncompliant  with certain continued listing standards of the Exchange as set
forth  in Part 10 of the  NYSE MKT  Company  Guide  (the  "Company  Guide").  In
particular,  based on the Company's quarterly report on Form 10-Q for the period
ended March 31, 2013, noncompliance was noted with respect to the requirement of
section  1003(a)(iv)  of the  Company  Guide  for NYSE MKT  issuers.  Additional
information and provisions regarding the NYSE MKT requirements are found in Part
10 of its company guide.

     In order to maintain listing of the Company's common stock on the NYSE MKT,
the  Company is  required  to submit a plan by August  19,  2013,  advising  the
Exchange of the actions the Company has taken, or will take, that would bring it
into compliance  with Section  1003(a)(iv) of the Company Guide by September 30,
2013.  The company plans to submit this plan by August 19, 2013. If the Exchange
accepts the plan,  then the Company may be able to continue  its listing  during
the plan  period,  during  which time the  Company  will be subject to  periodic
review to determine  whether it is making progress  consistent with the plan. If
the plan is not acceptable to the Exchange,  or even if accepted, if the Company
is not in compliance with the continued listing standards at the end of the plan
period or the Company  does not make  progress  consistent  with the plan during
such  period,  then the staff of the  Exchange  would be  expected  to  initiate
delisting  proceedings.  The Company may then appeal such a determination by the
staff of the Exchange in accordance with the provisions of section 1010 and Part
12 of the Company Guide.

     The Company's common stock continues to trade on the Exchange. The Exchange
has advised the Company  that the  Exchange is utilizing  the  financial  status
indicator fields in the Consolidate Tape Association's  Consolidated Tape System
and  Consolidated  Quote System High Speed Tape to identify  companies  that are
noncompliant  with the Exchange's  continued listing  standards.  The indicator,
"BC",  will  not  change  the  Company's  trading  symbol  itself,  but  will be
disseminated as an extension of the Company's symbol on the CTS and CQS whenever
the Company's trading symbol is transmitted with a quotation or trade.

Item 8.01.  Other Events.

     On July 19, 2013 the Company issued a press release  announcing its receipt
from the  Exchange of a notice of the  Company's  failure to satisfy a continued
listing  standard.  The full text of this press  release is  attached  hereto as
Exhibit 99.

                                       2
<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  July 19, 2013                      CEL-SCI CORPORATION



                                 By:  /s/ Geert R. Kersten
                                      ------------------------------------------
                                      Geert R. Kersten, Chief Executive Officer

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>form8kitem301exh99july-13.txt
<DESCRIPTION>EXHIBIT 99 PRESS RELEASE
<TEXT>
                                   EXHIBIT 99


<PAGE>


8229 Boone Boulevard, Suite 802                          COMPANY CONTACT:
Vienna, VA  22182.  USA                                  Gavin de Windt
Telephone (703) 506-9460                                 CEL-SCI Corporation
 www.cel-sci.com                                         (703) 506-9460

      CEL-SCI REPORTS ON NYSE MKT NONCOMPLIANCE NOTICE AND COMPLIANCE PLAN

Vienna,  VA, July 19, 2013 - CEL-SCI  Corporation  (NYSE MKT: CVM) reported on a
communication  from staff of its current listing exchange that it considered the
company  to be  noncompliant  with  certain  listing  requirements  based on its
quarterly  report for the period ended March 31, 2013.  The Company was given an
opportunity to maintain its listing by submitting a plan of compliance by August
19, 2013. The Company intends to submit such a plan by August 19, 2013.

Based on the company's  quarterly report on Form 10-Q for the period ended March
31, 2013,  noncompliance  was noted with respect to the  requirement  of Section
1003(a)(iv)  of the Company Guide for NYSE MKT. The exchange  indicated  that in
order to maintain its NYSE MKT listing, a plan should be submitted by August 19,
2013 addressing  regaining compliance with Section 1003(a)(iv) of the exchange's
Company  Guide by September  30, 2013.  Additional  information  and  provisions
regarding the NYSE MKT requirements are found in Part 10 of its Company Guide.

The  communication  and compliance  plan has no current effect on the listing of
the  company's  shares on the  exchange.  If the plan is not  acceptable  or the
company  does  not  make  sufficient  progress  under  the  plan or  reestablish
compliance  by  September  30,  2013,  then staff of the  exchange  may initiate
proceedings for delisting from the NYSE MKT. The company may then appeal a staff
determination  to initiate such  proceedings  in accordance  with the exchange's
Company Guide.

About CEL-SCI Corporation

CEL-SCI is  dedicated  to research and  development  directed at  improving  the
treatment  of cancer and other  diseases by  utilizing  the immune  system,  the
body's natural defense  system.  Its lead  investigational  therapy is Multikine
(Leukocyte Interleukin,  Injection), currently being studied in a pivotal global
Phase  III  clinical  trial.  CEL-SCI  is also  investigating  an  immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized  patients and as a
vaccine (CEL-2000) for Rheumatoid  Arthritis  (currently in preclinical testing)
using  its  LEAPS  technology   platform.   The  investigational   immunotherapy
LEAPS-H1N1-DC  treatment  involves  non-changing  regions of H1N1  Pandemic Flu,
Avian Flu (H5N1),  and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible  emergence of a new more  virulent  hybrid virus  through the
combination  of H1N1 and Avian  Flu,  or maybe  Spanish  Flu.  The  Company  has
operations in Vienna, Virginia, and in/near Baltimore, Maryland.

When used in this report,  the words "intends,"  "believes,"  "anticipated"  and
"expects"  and similar  expressions  are  intended  to identify  forward-looking
statements.  Such statements are subject to risks and uncertainties  which could
cause actual results to differ  materially  from those  projected.  Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential  products  that  can be  shown  to be safe  and  effective,  receiving
necessary  regulatory  approvals,  difficulties  in  manufacturing  any  of  the
Company's potential  products,  inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI  Corporation's  SEC filings,
including  but not  limited  to its  report  on Form  10-K  for the  year  ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking  statements which may be made to
reflect  the events or  circumstances  after the date  hereof or to reflect  the
occurrence of unanticipated events.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
